Ophthalmic diseases, particularly inherited retinal disorders, have become a major focus of the Adeno-associated Virus Vector-based Gene Therapy Market. The eye is an ideal target for gene therapy for several reasons: it is a small, contained organ, which reduces the required dose of the vector and minimizes systemic exposure. Additionally, the eye is considered an immunologically privileged...